Condition: Colorectal Carcinoma · Colorectal Neoplasms · Colorectal Tumor · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.
This description comes directly from the study's public registry record.
Maria Alessandra Calegari · +39 06 30156318 · mariaalessandra.calegari@policlinicogemelli.it
Maria Alessandra Calegari · +39 06 30156318 · eclypsestudy@policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Not Yet Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli, IRCCS | Roma, Italy | Recruiting |
| Ospedale Cardinale G. Panico | Tricase, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06640166